Skip to main content
SpringerLink
Log in

Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case–control study

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

After the wide use of linezolid (LZD), numerous reports of uncontrolled studies have suggested that LZD is associated with high rates of thrombocytopenia. We conducted this matched case–control study to identify the risk factors for LZD-induced thrombocytopenia in patients with acute myeloid leukemia (AML) during the period of myelosuppression.

Methods

We retrospectively retrieved laboratory and clinical data from the medical records of 180 Chinese with AML. Among them, 60 received ≥ 72 h of therapy with LZD during myelosuppression. The remaining patients who did not receive LZD therapy were matched individually in a ratio of 1:2 according to the basic characteristics of the LZD group.

Results

We found that in the LZD group, age, history of liver or kidney disease, the baseline level of bilirubin, and creatinine clearance rate (CCR) did not affect the recovery time of platelets. Patients who received LZD for more than 7 days during the period of myelosuppression had a significantly longer time of platelet recovery and platelet count increase.

Conclusion

The use of LZD > 7 days during the course of myelosuppression and the low level of albumin can prolong the time required for platelet count increase and recovery. Further study is needed to assess the potential adverse effects of LZD in larger AML patient populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References:

  1. Atallah E, Cortes J, O’Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547–51.

    Article  CAS  Google Scholar 

  2. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer-Am Cancer Soc. 2007;109:1705–14.

    CAS  Google Scholar 

  3. Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer-Am Cancer Soc. 2000;88:1710–4.

    CAS  Google Scholar 

  4. Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14:882–913.

    Article  CAS  Google Scholar 

  5. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-93.

    Article  Google Scholar 

  6. Nasraway SA, Shorr AF, Kuter DJ, O’Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 2003;37:1609–16.

    Article  CAS  Google Scholar 

  7. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37:517–20.

    Article  Google Scholar 

  8. Frey N, Jang JH, Szer J, et al. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019;6:e122–31.

    Article  Google Scholar 

  9. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51:1431–4.

    Article  CAS  Google Scholar 

  10. Sipahi OR, Bardak S, Turhan T, et al. Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases. Scand J Infect Dis. 2011;43:757–64.

    Article  Google Scholar 

  11. Kjollerstrom P, Brito MJ, Gouveia C, Ferreira G, Varandas L. Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand J Infect Dis. 2011;43:556–9.

    Article  CAS  Google Scholar 

  12. Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm-Net. 2014;36:795–9.

    Article  CAS  Google Scholar 

  13. Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31:2126–33.

    Article  CAS  Google Scholar 

  14. Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17:382–7.

    Article  CAS  Google Scholar 

  15. Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36:795–9.

    Article  CAS  Google Scholar 

  16. Zhou D, Shi T, Zhao S, Zhu J, Zhu L, Yang X, Xie W, Ye X. Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy. J Clin Pharm Ther. 2020;45(4):755–8.

    Article  CAS  Google Scholar 

  17. Nedved AN, DeFrates SR, Hladnik LM, Stockerl-Goldstein KE. Effect of linezolid on hematologic recovery in newly diagnosed acute myeloid leukemia patients following induction chemotherapy. Pharmacotherapy. 2016;36:1087–94.

    Article  CAS  Google Scholar 

  18. Kato H, Hamada Y, Hagihara M, et al. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy. J Infect Chemother. 2015;21:707–12.

    Article  CAS  Google Scholar 

  19. Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33:98–9.

    Article  CAS  Google Scholar 

  20. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345–51.

    Article  CAS  Google Scholar 

  21. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775–80.

    Article  CAS  Google Scholar 

  22. Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2012;44:60–4.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Health Commission of Zhejiang Province under

Grant 2018KY577.

Author information

Author notes

  1. C. Chen and Y. Li contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, People’s Republic of China

    Can Chen, Jingdi Yu & Qian Shenxian

  2. Department of Critical Care Medicine, Hangzhou First People’s Hospital Zhejiang University School of Medicine, Hangzhou, People’s Republic of China

    Yiwei Li

Authors
  1. Can Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yiwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingdi Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qian Shenxian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CC conceived and designed the study, and drafted the manuscript. YL and JY collected, analyzed and interpreted the experimental data. SQ revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Qian Shenxian.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by Ethical Committee of Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine and conducted in accordance with the ethical standards.

Informed consent

Subjects signed the informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, C., Li, Y., Yu, J. et al. Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case–control study. Clin Transl Oncol 24, 540–545 (2022). https://doi.org/10.1007/s12094-021-02711-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02711-9

Keywords

Search

Navigation